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Abstract  
This study aims to identify periods of elevated risk of drug related mortality during 
methadone maintenance treatment (MMT) in primary care using a cohort of 3,162 
Scottish drug users between January 1993 and February 2004. Deaths occuring during 
treatment or within 3 days after last methadone prescription expired were considered as 
cases “on treatment”. Fatalities occuring 4 days or more after leaving treatment were 
cases “off treatment”. 64 drug related deaths were identified. The greatest risk of drug 
related death was in the first 2 weeks of treatment (Adjusted hazard ratio 2.60, 95% CI 
1.03 to 6.56). Risk of drug related death was lower after the first 30 days following 
treatment cessation, relative to the first 30 days off treatment. History of psychiatric 
admission was associated with increased risk of drug related death in treatment. 
Increasing numbers of treatment episodes and urine testing were protective. History of 
psychiatric admission, increasing numbers of urine tests and co-prescriptions of 
benzodiazepines increased the risk of mortality out of treatment. The risk of drug related 
mortality in MMT is elevated during periods of treatment transition, specifically 
treatment intitiation and the first 30 days following treatment drop-out or discharge. 
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Introduction 
Drug misuse is a major public health problem in Scotland and elsewhere.(ISD, 2004) 
Heroin users are at high risk of premature mortality, with an annual mortality six times 
higher than that for a general, age matched population, with more than two-thirds of these 
deaths due to drug overdose.(Gossop, Stewart, Treacy, & Marsden, 2002) Methadone, is 
the most common form of treatment for heroin misuse in the UK.(McCowan, Kidd, & 
Fahey, 2009) Methadone maintenance programmes are commonly provided by general 
practitioners in the UK, with methadone prescribing in primary care increasing in the 
1990s.(Morgan, Griffiths, & Hickman, 2006; Strang & Sheridan, 2003) Despite evidence 
supporting the benefits of methadone maintenance treatment (MMT), methadone itself 
has been associated with drug-related deaths.(Cairns, Roberts, & Benbow, 1996; 
Drummer, Opeskin, Syrjanen, & Cordner, 1992; Harding-Pink, 1993; Morgan, et al., 
2006) The risk of overdose has been shown to vary over the course of MMT, with several 
studies reporting an elevated risk of fatal overdose in the initial weeks of MMT.(Buster, 
van Brussel, & van den Brink, 2002;  Caplehorn & Drummer, 1999; Degenhardt, et al., 
2009; Perret, Deglon, Kreek, Ho, & La Harpe, 2000; Deborah Zador & Sunjic, 2000) 
These effects may arise due to inadequate clinical assessment and review of a patients‟ 
tolerance prior to initiating methadone, thus resulting in overdose.(Buster, et al., 2002; 
Caplehorn & Drummer, 1999) Therefore cautious prescribing of methadone during the 
first two weeks has been advised based on the risk of cumulative toxicity from 
methadone.(Zador & Sunjic, 2000)  
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The risk of methadone overdose must be balanced against the risk of newly inducted 
patients resorting to illicit drug use to compensate for withdrawal symptoms as they wait 
for the stabilising effects of methadone to take effect. Such patients may voluntarily 
withdraw from treatment or, in the case of strict methadone delivery programmes that do 
not tolerate opiate drug use, be expelled from treatment. Studies have shown that patients 
who leave methadone programmes have increased mortality risks relative to those 
remaining in treatment.( Caplehorn, Dalton, Haldar, Petrenas, & et al., 1996; Clausen, 
Anchersen, & Waal, 2008; Davoli, et al., 2007; Fugelstad, Stenbacka, Leifman, Nylander, 
& Thiblin, 2007; Langendam, van Brussel, Coutinho, & van Ameijden, 2001; Zanis & 
Woody, 1998) A recent prospective cohort study of Italian opiate users found that the risk 
of overdose following treatment cessation was more than three times higher in the first 30 
days after treatment drop-out or discharge compared to the subsequent 31 days or more 
after treatment.(Davoli, et al., 2007) However, these effects are not specific to MMT but 
rather a range of treatments for heroin dependence, including MMT, methadone 
detoxification, other pharmacological detoxification and psychological interventions.  
 
The aim of this study is to examine risk of drug related mortality during periods of 
treatment transition, specifically treatment initiation and the first month following MMT 
cessation, adjusting for patient characteristics and treatment factors, in a primary care 
setting in a defined geographical population. 
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Materials and methods 
 
Study design and setting 
A retrospective cohort study design was used. The study population consisted of people 
resident in Tayside, Scotland, who were registered with a general practitioner and were 
prescribed and dispensed liquid methadone between January 1993 and February 2004. 
Every person registered with a general practitioner in Tayside is assigned a 10 digit 
unique identifier, the Community Health Index (CHI) number, which is used in all 
encounters with the National Health Service (NHS) in the region. 
 
Procedures 
Data on age, sex and postcode for each patient who was dispensed at least one liquid 
methadone prescription between 1/1/1993 and 28/2/2004 were extracted. Patients who 
were under 16 or over 65 years of age at the time of first prescription were excluded from 
the analysis. The CHI number was used to link these records to all dispensed prescribing, 
hospital admissions, psychiatric unit admissions, urine testing and mortality. Standard 
operating procedures at the Health Informatics Centre, Univeresity of Dundee were  
followed to ensure anonymisation of the dataset.(Wilson, 2004)  
 
The movement of patients in and out of treatment was tracked using methadone 
prescriptions. A patient‟s first appearance in the dataset was recorded as their first 
treatment episode during the observation period. Each record of a prescription for 
methadone contained the date, dose, quantity and strength of the prescription. The 
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coverage is computed as the quantity divided by the daily dose and is expressed in days. 
The length of a patient‟s treatment episode was calculated using the coverage of the 
patient‟s prescription. If a patient received a new prescription within three days of the end 
of the previous prescription‟s coverage, then they were considered to be still in treatment. 
When a patient did not receive a new methadone prescription within three days after the 
end of coverage of a prescription, that patient was considered to have ceased treatment. 
This „off treatment‟ period continued until a patient re-entered treatment as indicated by 
the presence of a new methadone prescription. A 3 day cut-off was applied according to 
1999 UK guidelines, which indicate that a patient may lose their tolerance to methadone 
after 3 days and need to be reassessed for intoxication and withdrawal before MMT is 
recommenced.(Department of Health (England) & and the devolved administrations, 
1999) This information was used to calculate number and duration of treatment episodes 
for each patient. Overuse of methadone occured when a patient obtained a new 
prescription before the end of coverage of the previous prescription. In accordance with 
UK prescribing guidelines, patients were categorised as below, within or above the 
recommended methadone maintenance range of 60mg to 120 mg daily.(Department of 
Health (England) & and the devolved administrations, 2007) 
 
The main outcome measure was drug related mortality recorded on the General Registry 
Office death certificate. Drug related deaths occuring during treatment or within three 
days after the final days‟ coverage of the last methadone prescription were considered as 
cases during treatment. Fatalities occurring from the fourth day after the final days‟ 
7 
 
coverage of the last methadone prescription were considered as drug related deaths „off 
treatment‟. 
 
A number of additional variables were defined as potential explanatory or confounding 
variables for drug related mortality. The Carstairs deprivation score to categorise 
socioeconomic status on the basis of  home postcode was calculated using 2001 census 
data and re-expressed as categories.(Carstairs & Morris, 1990) The Charlson comorbidity 
index was calculated from patient‟s hospital discharge records for co-morbid disease 
groups using  ICD-9 and ICD-10 codes in the hospital admission records and encashed 
prescribing records for respiratory disease, AIDS, peptic ulcers, cancer, metastatic 
tumours, diabetes, myocardial infarction, connective tissue disorders and 
dementia.(Deyo, Cherkin, & Ciol, 1992; Sundararajan, et al., 2004) The Charlson index 
scores were categorised into three groups: low (0), medium (1 to 2) and high (≥ 3) 
morbidity. Psychiatric admissions were recorded for both psychiatric and acute hospitals. 
Prescribing records were also used to identify all patients who had received  
benzodiazepines. The dates and results of urine tests for opiates were recorded for each 
patient. Frequent or moderate urine testing is seen to act as a deterrent to illicit opiate use 
and thereby improves treatment outcomes. Patients with missing data that prevented 
calculation of all periods of coverage were excluded from the analysis. 
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Analysis procedures 
We report data statistics as number (percentage) of people for categorical variables. 
Continuous variables that do not follow a normal distribution were tested using the 
Shapiro-Wilks test for skewness and reported as the median and interquartile range. 
 
Three Cox proportional hazards models with both time dependent and fixed covariates 
were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for drug 
related mortality during periods of treatment transition. The first model focused on drug 
related mortality overall. The remaining two models represent subgroup analyses of drug 
related mortality in treatment and off treatment. Patients were defined by their treatment 
status at the end of the study or at the time of death. Treatment status was defined 
according to previous studies (Buster, et al., 2002; Davoli, et al., 2007; Degenhardt, et al., 
2009) as : 1-2 weeks in treatment; 3-10 weeks in treatment; >10 weeks in treatment;  ≤ 30 
days off treatment; > 30 days off treatment. 
 
Covariates that had a statistically significant univariate p value (p<0.05) were included in 
the multivariate model. Log transformations were applied to covariates with a highly 
right-skewed distribution to reduce the effects of extreme values: number of times 
overusing methadone; number of MMT treatment episodes; number of urine tests for 
opiate use; and  number of prescriptions for benzodiazepines.  The proportional hazards 
assumption was assessed using trend tests of the Schoenfeld residuals with those that 
failed the assumption entered as continuous time dependent covariates.(Bradburn, Clark, 
Love, & Altman, 2003) Hazard ratios for variables treated as time dependent covariates 
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vary over time and are reported at the median survival time. LMAX and DFBETA 
measures were used to test for influential observations and covariates, respectively. Stata 
version 11 was used for all statistical analyses. 
 
Results 
Description of the study population 
A cohort of 3,162 people were prescribed and dispensed methadone during the 12 year 
study – a total of 14,597 person years with a median follow up of 3.6 (interquartile range 
1.5 to 7.5) years. 
 
INSERT TABLE 1 HERE 
 
Table 1 describes the study population. Over half the cohort were aged less than 30 years 
at the time of first prescription and 45% were from the lowest socioeconomic groups 
(Carstairs categories 6 and 7). One third of patients had a record of psychiatric admission, 
and a history of co-prescription of benzodiazepines was high. Half the patients had at 
least one urine test and were found to overuse their methadone on at least one occasion. 
The methadone dose at last prescription was lower than the recommended adequate 
maintenance dose of 60-120mg daily for 74% of patients, with only 25% receiving the 
recommended adequate maintenance dose (see Table 1). The median number of MMT 
treatment episodes was 4 (interquartile range 1-11), with a median of 31 days 
(interquartile range 17 to 41.5 ) per treatment episode and  40.5 (interquartile range 20 to 
575) days per off treatment episode.   
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Drug related mortality and timing of death  
During the 12 year study period, 184 people died. Cause of death was available for 145 
(79%) of these people from General Registry Office records. The remaining 39 people 
were identified as dead from the CHI number register, but cause of death could not be 
ascertained as there was no General Registry Office record. Codes that relate to „drug 
related‟ were recorded as the principal cause of death in 64 (44%) cases. 
 
Of the 64 drug-related deaths, 31 occurred during treatment (eight in the first two weeks 
after entering or re-entering treatment, 18 died during the 3rd to the 10th week and 5 died 
more than 10 weeks after entering or re-entering treatment). Thirty-three patients died 
after treatment drop-out or discharge, 11 died in the first 30 days following treatment 
cessation.  
 
High risk periods 
Table 2 shows the risk of drug related mortality at different time points in and out of 
methadone treatment, adjusted for significant covariates. The risk of mortality is 
significantly lower after the first month following treatment drop-out or discharge 
relative to the first 30 days following treatment cessation (Adjusted HR 0.06, 95% CI 
0.02 to 0.14, p<0.001). However, the risk of mortality during the first two weeks of 
treatment is substantially higher than the off treatment risk period of less than one month 
post treatment with an adjusted HR 2.60  (95% CI 1.03 to 6.56, p<0.05). Greater 
movement in and out of treatment, a history of psychiatric admission and co-prescribing 
of benzodiazepines remained independently associated with increased risk of drug related 
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mortality. Older age at time of first prescription was found to be protective of drug 
related mortality (table 2). 
 
INSERT TABLE 2 HERE 
 
A more detailed look at the risk of drug related mortality during MMT is shown in table 
3. The risk of drug related death was markedly elevated in the first two weeks following 
treatment intitiation. Retention in treatment for 3-10 weeks and greater than 10 weeks 
was found to be protective against drug related mortality. These effects remained after 
adjusting for significant covariates. A history of psychiatric admission was found to 
increase the risk of drug related death in treatment (Adjusted HR 9.51, 95% CI 3.15 to 
28.69, p <0.001). Increasing numbers of treatment episodes and urine testing for opiates 
were found to be protective (table 3). 
 
INSERT TABLE 3 HERE 
 
As displayed in the overall risk model, the risk of mortality during the first 30 days 
following treatment cessation has an increased risk of mortality relative to the subsequent 
31 days or more after leaving treatment (Adusted HR 0.17, 95% CI 0.06 to 0.47, p 
<0.01). A history of psychiatric admission (Adjusted HR 8.48, 95% CI 3.44 to 20.94, p 
<0.001) and increasing numbers of urine tests for opiates and co-prescriptions for 
benzodiazepines increased the risk of mortality out of treatment (table 4).  
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INSERT TABLE 4 HERE 
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Discussion 
As hypothesised, periods of transition, particularly treatment initiation and the first month 
following discontinuation, were identified as high risk periods for drug related deaths in 
and out of treatment. This study also highlights the chronic relapsing nature of drug use. 
Few patients were retained in treatment for the duration of the observation period, rather 
patients moved in and out of treatment, experiencing multiple treatment episodes and 
treatment discontinuation. These findings are consistent with previous studies.(Bell, 
Burrell, Indig, & Gilmour, 2006; Degenhardt, et al., 2009; Nosyk, et al., 2009)   
 
This study was the first study to consider sub-group analyses, examining the influence of 
patient and treatment factors on drug related deaths overall, and on deaths in treatment 
and following treatment cessation. In the overall model, risk of drug related death 
increased with greater numbers of treatment episodes, a history of psychiatric admission 
and co-prescribing of benzodiazepines. Greater numbers of treatment episodes indicates 
greater movement in and out of treatment during the study period which may arise due to 
a chaotic lifestyle with increased exposure to the known risk periods, the first two weeks 
in treatment and first month off treatment. The increased hazard of death among those 
with co-prescriptions for benzodiazepines is consistent with previous research (Man, 
Best, Gossop, Stillwell, & Strang, 2004) and toxicological reports of drug related 
deaths.(Zador, et al., 2005). 
 
History of psychiatric admission remained significantly associated with an increased risk 
of death in treatment. Increasing numbers of urine tests in treatment were protective 
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against mortality in treatment.  The protective effects of urine testing may arise due to 
greater monitoring of patients in treatment which may equate with greater contact with 
health professionals. In contrast to the overall model, number of treatment episodes was 
found to be associated with reduced mortality in treatment. An Australian study reported 
similar findings, with increased prior treatment episodes associated wtih reduced risk 
during treatment induction.(Degenhardt, et al., 2009) Degenhardt and colleagues also 
found that the majority of these induction deaths occured in the first two treatment 
episodes. Similarly, we found that half of the drug related deaths occurring in the first 
two weeks of treatment occured in the first three treatment episodes. The protective 
effects of number of treatments may reflect selection effects, with those at hightest risk 
dying early.(Degenhardt, et al., 2009) Furthermore, patients experiencing more treatment 
episodes  are likely to have more regular contact with health services which may be 
protective against drug related mortality in treatment. In addition, a recent Canadian 
study of MMT found that patients experiencing multiple treatment episodes tended to 
stay in treatment for progressively longer periods in later episodes.(Nosyk, et al., 2009) 
We found similar effects in this study, suggesting greater stability over time which may 
offer protection against mortality in treatment. Similarly, a recent study of the Edinburgh 
Addiction Cohort found that for each additional year of methadone therapy the hazard of 
death before long term heroin cessation fell 13%.(Kimber, et al., 2010) It is also 
important to note that number of treatment episodes was not identified as time dependent 
in the „in‟ treatment model. Failure to account for time may have confounded our results.  
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In relation to drug related deaths out of treatment, the risk is greatest in the first month 
following treatment cessation. The risk of death increased among those with a history of 
psychiatric admission and co-prescribing of benzodiazepines. In addition, those with 
greater numbers of urine testing off treatment had an increased hazard of mortality off 
treatment. It is interesting to note that number of treatment episodes, although not 
significant at a multivariate level of analysis, increased the risk of mortality off treatment. 
It is possible that the negative effects of multiple treatment and cessation episodes are 
greatest during off treatment periods. However, this is speculative and would require 
further investigation.  
 
Strengths and limitations 
The strengths of the study include the study size, long duration of follow-up and detailed 
prescribing, monitoring and management information over time. In addition, NICE 
guidelines indicate that most randomised controlled trials of methadone therapy in the 
treatment of drug dependence were done in ouptatient of inpatient settings or specialist 
treatment centres.(National Institute for Health and Clinical Excellence.Methadone and 
buprenorphine for the management of opioid dependence, 2007) This study focuses on 
identifying periods of increased mortality risk among community based patients. 
 
Due to the observational study design, causal interpretations can be only plausibly 
inferred. The choice of high risk periods (i.e. the first two weeks in treatment, the first  
thirty days off treatment) were chosen based on published evidence.(Buster, et al., 2002; 
Davoli, et al., 2007) A different choice of high risk periods may influence the relative 
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importance of the different risk factors associated with mortality. As mortality was a 
relatively rare event, this study may have been underpowered to detect potentially 
significant contributions of some factors. In addition, we could not identify cause of 
death for 39 cases of the total cohort who died during the study period. Other 
shortcomings relate to the limited details regarding on and off treatment episodes. In 
relation to „on‟ treatment episodes we do not have infomation regarding supervised 
consumption or other therapeutic experiences such as counselling. In addition, we have 
limited information regarding patient circumstances during „off‟ treatment episodes. 
Time after discontinuation of treatment may be spent in prison, or a patient may relapse 
or fully abstain from illicit drug use. Such differences are likely to confound the ability of 
our study to accurately stratify risk of mortality off treatment. However, we do know that 
even if a patient left Tayside during an „off treatment‟ episode they did not register with 
another GP outside Tayside. Although we adjusted for several confounders, other 
confounders such as addiction severity, route of admission, imprisonment and living 
situation, which we have not accounted for may bias the results. Finally, the 
generalisability of these results may be limited as the movement of patients in and out of 
treatment was more frequent in this cohort compared to other longitudinal studies.(Bell, 
et al., 2006; Degenhardt, et al., 2009; Nosyk, et al., 2009) A median of 4 treatment 
episodes was recorded in our study with an interquartile range of 1-11 treatment episodes. 
A recent Canadian study of MMT over an 11 year follow-up recorded a median of  two 
treatment episodes with an IQR 1-3.(Nosyk, et al., 2009) However, this discrepancy may 
be an artefact of differential definitions of when an „off‟ treatment episode begins. Our 
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study considered treatment cessation to occur after 3 days compared to a 7 day cut-off  in 
the Canadian study. 
 
Implications 
Notwithstanding these limitations, the current findings have important implications for 
practice and policy. Firstly, given the increased risk of mortality during periods of 
treatment transition, efforts should be made to encourage patient retention in MMT 
programmes as part of a drug overdose prevention strategy. The importance of retaining 
patients in treatment is also highlighted as greater frequency of movement in and out of 
treatment was found to be related to drug related mortality. A post-treatment follow-up 
should also be considered following treatment cessation, particularly in the first month 
following treatment drop-out or discharge. Similarly, a stringent clinical assessment and 
review of a patients‟ tolerance prior to starting MMT is important to avoid drug-overdose 
during treatment induction espcially for those with fewer previous treatment episodes. 
Previous studies have also highlighted that opiate users with help-seeking behaviours are 
more likely to attempt suicide.(Ghodse, Sheehan, Taylor, & Edwards, 1985) Therefore, 
clinicians should also seek to identify those patients with suicidal ideation at the time of 
treatment commencement. Finally, the delivery of MMT in primary care may not be 
appropriate for all patients, particularly those patients with psychiatric co-morbidities. 
Patients with a history of psychiatric admission were identified as having an elevated risk 
of mortality both on and off treatment, however further evidence is required to stratify the 
influence of various psychiatric conditions on mortality during MMT in primary care. 
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Conclusions 
This community based study shows an elevated risk of drug related mortality during 
periods of treatment transition, particularly the first two weeks of treatment initiation and 
the first 30 days following treatment drop-out or discharge. The quality of care could be 
improved by ensuring greater monitoring of methadone patients when starting or 
restarting a patient on MMT. In addition, a post-treatment follow-up should also be 
considered following treatment cessation, particularly in the first month following 
treatment drop-out or discharge. 
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Table 1. Description of the study population, according to whether patients survived or 
died 
Characteristics Surviving 
patients 
(n=3,098) 
Drug-related 
death ‘in 
treatment’ 
(n=31) 
Drug-related 
death ‘off 
treatment’ 
 (n=33) 
Total 
(n=3,162) 
     
Male sex 2003 (64.7) 18 (58.1) 27 (81.8) 2048 (64.8) 
Age:     
    16-19 297 (9.6) 1 (3.2) 2 (6.1) 300 (9.5) 
    20-29 1413 (45.6) 21 (67.7) 22 (66.7) 1456 (46.1) 
    30-39 795 (25.7) 7 (22.6) 7 (21.2) 809 (25.6) 
    40-65 593 (19.1) 2 (6.5) 2 (6.1) 597 (18.9) 
Social class (Carstairs)
a
: 
    1 56 (1.9) 0 0 56 (1.8) 
    2 243 (8.0) 0 0 243 (7.9) 
    3 501 (16.6) 4 (12.9) 4 (12.1) 509 (16.5) 
    4 332 (11.0) 4 (12.9) 2 (6.1) 338 (10.9) 
    5 537 (17.7) 5 (16.1) 8 (24.2) 550 (17.8) 
    6 782 (25.8) 9 (29.0) 13 (39.4) 804 (26.0) 
    7 576 (19.0) 9 (29.0) 6 (18.2) 591 (19.1) 
Comorbidity (Charlson Index): 
   0 2752 (88.8) 22 (71.0) 26 (78.8) 2800 (88.6) 
   1-2 221 (7.1) 3 (9.7) 5 (15.2) 229 (7.2) 
   ≥ 3 125 (4.0) 6 (19.4) 2 (6.1) 133 (4.2) 
Psychiatric admission  988 (31.9) 27 (87.1) 25 (75.8) 1040 (32.9) 
Urine tests for opiates  1542 (49.8) 17 (54.8) 14 (42.4) 1573 (49.8) 
Co-prescribing of 1974 (63.7) 30 (96.8) 30 (90.9) 2034 (64.3) 
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Benzodiazepines  
Characteristics Surviving 
patients 
(n=3,098) 
Drug-related 
death ‘in 
treatment’ 
(n=31) 
Drug-related 
death ‘off 
treatment’ 
 (n=33) 
Total 
(n=3,162) 
Overusing methadone  1521 (49.1) 25 (80.7) 22 (66.7) 1568 (49.6) 
Last methadone dose:     
   < 60 mg 2298 (74.2) 26 (83.9) 25 (75.8) 2349 (74.3) 
   60 – 120 mg 781 (25.2) 5 (16.1) 8 (24.2) 794 (25.1) 
    ≥ 120 mg 19 (0.6) 0 0 19 (0.6) 
Median number MMT 
episodes 
3 (1-11) 7 (4-13) 5 (1-7) 4 (1-11) 
Median days In 
treatment 
31 (17-41) 43 (31-59) 38.5 (29.5-70) 31 (17-41.5) 
Median days Off 
treatment  
43.5 (20-588) 24 (17-25) 20 (14-54) 40.5 (20-575) 
* Data are presented as frequency (percentage) or median (interquartile range) 
a
 The number of patients does not add up the total because of some missing data 
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Table 2. Risk of drug related mortality across different risk periods „in‟ and „off‟ 
treatment 
 
Characteristics Unadjusted hazard ratio 
(95% CI) 
Adjusted hazard 
ratio 
 (95% CI) 
Last treatment episode   
<30 days off methadone (reference) 1.0 1.0 
>30 days off methadone 0.32 (0 .15 to 0.65)** 0.06 (0.02 to 0.14)*** 
1-2 weeks on  methadone 2.27 (0.91 to 5.64) 2.60 (1.03 to 6.56)* 
>3 weeks on methadone 1.85 (0 .91 to 3.80) 1.97 (0.95 to 4.09) 
Male sex 1.19 (0 .70 to 2.04) NA 
Age (per year) 0.96 (0.93 to 0.99)* 0.96 (0.93 to 0.99)** 
Social class (Carstairs):   
    1-4 (reference) 1.0 NS† 
    5-7 1.86 (1.03 to 3.37)*    NS† 
Comorbidity (Charlson Index):   
   0 (reference) 1.0 NS† 
   1-2 1.90 (0.90 to 4.01)  NS† 
   ≥ 3 2.61 (1.23 to 5.52)*   NS† 
Number of times overusing methadone†   1.46 (1.14 to 1.87)** NS† 
Last methadone dose:   
   < 60 mg (reference) 1.0 NA 
   ≥ 60 mg 0.75 (0.41 to 1.37)     NA 
Number of MMT episodes† 1.67 (1.27 to 2.20)*** 1.83 (1.34 to 2.50)*** 
Psychiatric admission (ever) 6.93 (3.70 to 13.00)***   7.04 (3.55 to 13.97)*** 
Number of urine tests for opiates† 1.38 (1.06 to 1.79)* NS† 
Number of co-prescriptions for Benzodiazepines 1.34 (1.16 to 1.54)*** 1.39 (1.16 to 1.68)*** 
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*p<0.05; **p<0.01; ***P<0.001; † time dependent variable; NA covariates that were non-significant 
(p>0.05) at the univariate level of analysis were not included in the multivariate model; NS† Social Class, 
co-morbidity, number of times overusing methadone and number of urine tests for opiates were included in 
the original multivariate analysis but they did not remain independently significant. Therefore the model 
was retested removing these variables to improve the power of the model by reducing the number of 
variables given the small number of events (64).  
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Table 3. Risk of drug related mortality across different risk periods „in‟ treatment 
Characteristics Unadjusted hazard ratio 
(95% CI) 
Adjusted hazard ratio 
 (95% CI) 
Last on treatment episode   
1-2 weeks on  methadone(reference) 1.0 1.0 
3-10 weeks on methadone 0.43 (0.19 to 0.99)* 0.40 (0.17 to 0.95)* 
>10 weeks on methadone 0.26 (0.08 to 0.80)* 0.10 (0.03 to 0.35)*** 
Male sex 0.68 (0.33 to 1.38) NA 
Age (per year) 0.99 (0.94 to 1.04) NA 
Social class (Carstairs):   
    1-4 (reference) 1.0 NA 
    5-7 0.96 (0.43 to 2.16) NA 
Comorbidity (Charlson Index):   
   0 (reference) 1.0 NS† 
   1-2 1.45 (0.43 to 4.84) NS† 
   ≥ 3 3.02 (1.22 to 7.52)* NS† 
Number of times overusing methadone 0.46 (0.29 to 0.72)**  NS† 
Last methadone dose:   
   < 60 mg (reference) 1.0 NA 
   ≥ 60 mg 0.42 (0.16 to 1.10) NA 
Number of MMT episodes 0.14 (0.09 to 0.24) *** 0.08 (0.04 to 0.16)*** 
Psychiatric admission (ever) 6.05 (2.10 to 17.41)** 9.51 (3.15 to 28.69)*** 
Number of urine tests for opiates 0.37 (0.24 to 0.58)*** 0.57 (0.35 to 0.91)* 
Number of co-prescriptions for Benzodiazepines 1.15 (0.91 to 1.44) NA 
*p<0.05; **p<0.01; ***P<0.001; NA covariates that were non-significant (p>0.05) at the univariate level 
of analysis were not included in the multivariate model; NS† Comorbidity and number of times overusing 
methadone were included in the original multivariate analysis but did not remain independently significant. 
Therefore the model was retested removing these two variables to improve the power of the model by 
reducing the number of variables given the small number of events (31).  
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Table 4. Risk of drug related mortality across different risk periods „off‟ treatment 
Characteristics Unadjusted hazard ratio 
(95% CI) 
Adjusted hazard ratio 
 (95% CI) 
Last off  treatment episode   
<30 days off methadone (reference) 1 1.0 
>30 days off methadone 0.41 (0.20 to 0.84)* 0.17 (0.06 to 0.47)** 
Male sex 2.30 (0.95 to 5.57) NA 
Age (per year) 0.96 (0.92 to 1.00) NA 
Social class (Carstairs):   
    1-4 (reference) 1  
    5-7 2.63 (1.09 to 6.38)* NS† 
Comorbidity (Charlson Index):   
   0 (reference) 1  NA 
   1-2 2.30 (0.88 to 6.00) NA 
   ≥ 3 1.40 (0.33 to 5.92) NA 
Number of times overusing methadone 1.15 (0.86 to 1.53) NA 
Last methadone dose:   
   < 60 mg (reference) 1 NA 
   ≥ 60 mg 0.98 (0.44 to 2.18) NA 
Number of MMT episodes† 1.37 (1.06 to 1.79)* 1.27 (0.95 to 1.70) 
Psychiatric admission (ever) 5.87 (2.65 to 13.01)*** 8.48 (3.44 to 20.94)*** 
Number of urine tests for opiates† 1.86 (1.19 to 2.93)** 1.72 (1.01 to 2.93)* 
Number of co-prescriptions for Benzodiazepines 1.29 (1.07 to 1.56)** 1.31 (1.02 to 1.66)* 
 
*p<0.05; **p<0.01; ***P<0.001; † time dependent variable; NA covariates that were non-significant 
(p>0.05) at the univariate level of analysis were not included in the multivariate model; NS† Social class 
was included in the original multivariate analysis but did not remain significant. Therefore the model was 
retested removing social class to improve the power of the model by reducing the number of variables 
given the small number of events (33).  
